Quadrant Capital Group LLC Boosts Stake in Merck & Co., Inc. $MRK

Quadrant Capital Group LLC increased its stake in Merck & Co., Inc. (NYSE:MRK) by 27.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 86,654 shares of the company’s stock after purchasing an additional 18,764 shares during the quarter. Quadrant Capital Group LLC’s holdings in Merck & Co., Inc. were worth $7,273,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of MRK. One Charles Private Wealth Services LLC lifted its position in shares of Merck & Co., Inc. by 3.3% during the 3rd quarter. One Charles Private Wealth Services LLC now owns 3,464 shares of the company’s stock valued at $291,000 after buying an additional 111 shares in the last quarter. Dakota Community Bank & Trust NA increased its holdings in Merck & Co., Inc. by 3.4% in the 3rd quarter. Dakota Community Bank & Trust NA now owns 3,566 shares of the company’s stock worth $299,000 after acquiring an additional 116 shares in the last quarter. Security National Bank of Sioux City Iowa IA increased its holdings in Merck & Co., Inc. by 3.6% in the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 3,402 shares of the company’s stock worth $286,000 after acquiring an additional 119 shares in the last quarter. Investors Research Corp raised its stake in Merck & Co., Inc. by 1.3% during the 3rd quarter. Investors Research Corp now owns 9,325 shares of the company’s stock worth $783,000 after acquiring an additional 120 shares during the period. Finally, Trust Point Inc. raised its stake in Merck & Co., Inc. by 0.8% during the 3rd quarter. Trust Point Inc. now owns 14,834 shares of the company’s stock worth $1,245,000 after acquiring an additional 120 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Trading Up 0.0%

Merck & Co., Inc. stock opened at $117.14 on Wednesday. The stock has a market cap of $289.61 billion, a P/E ratio of 16.09, a PEG ratio of 2.27 and a beta of 0.27. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14. The firm’s 50 day moving average price is $114.64 and its 200-day moving average price is $99.14.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The firm had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter in the previous year, the firm earned $1.72 earnings per share. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be paid a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a yield of 2.9%. Merck & Co., Inc.’s payout ratio is presently 46.70%.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 121,573 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the transaction, the executive vice president owned 68,916 shares of the company’s stock, valued at $8,211,341.40. This represents a 63.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Richard R. Deluca sold 37,685 shares of the firm’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $120.92, for a total value of $4,556,870.20. Following the transaction, the executive vice president owned 160,174 shares of the company’s stock, valued at approximately $19,368,240.08. The trade was a 19.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 320,176 shares of company stock worth $38,281,735. 0.09% of the stock is owned by corporate insiders.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Late‑stage trial wins for oncology and HIV programs (KEYTRUDA, WELIREG regimens and DOR/ISL HIV therapy) that show improved survival and broadened indications—these readouts raise near‑term revenue potential and long‑term pipeline value. Merck Trial Wins Shape Oncology And HIV Prospects For Investors
• Positive Sentiment: Stock moving higher within the S&P 500 — market‑level strength and rotation into large pharma/defensive names is supporting MRK’s price action. Merck & Co. (NYSE:MRK) Moves Higher Within S&P 500 Index Amid Gains
• Positive Sentiment: Expanding neuroendocrine carcinoma market and other oncology indications — market forecasts to 2036 increase the addressable opportunity for Merck’s targeted therapies, supporting longer‑term growth assumptions for KEYTRUDA and companion assets. Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight
• Neutral Sentiment: Vaccine franchise market reports (Ervebo, M‑M‑R II, Pneumovax 23, Elonva) highlight steady long‑term demand and niche growth opportunities—positive background but unlikely to move near‑term results absent new approvals or major contract wins. Ervebo (Merck & Co) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F
• Negative Sentiment: Persistent weakness in Gardasil sales (down ~39% in 2025 with weak China demand) — management expects no near‑term rebound, which pressures top‑line growth and investor expectations for vaccine contribution to revenue. Will Weak Gardasil Sales Continue to Weigh on MRK’s Top Line in 2026?
• Negative Sentiment: RBC caution on Winrevair — analyst says the COPD candidate must show a ≥20‑meter improvement in 6‑minute walk to restore confidence; this raises clinical/regulatory uncertainty that could limit upside for that program. Merck’s Winrevair Must Show Walk Distance Improvement to Build Confidence, RBC Says

Analysts Set New Price Targets

A number of research firms have weighed in on MRK. Zacks Research lowered shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research report on Friday, January 9th. UBS Group raised their price objective on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Wells Fargo & Company lifted their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research note on Wednesday, February 4th. Royal Bank Of Canada started coverage on shares of Merck & Co., Inc. in a report on Wednesday, February 25th. They issued an “outperform” rating and a $142.00 target price for the company. Finally, Scotiabank increased their price target on Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “sector outperform” rating in a research note on Thursday, December 4th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $125.88.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.